You are here: Home » Companies » News
Business Standard

Advent International to acquire controlling stake in RA Chem Pharma

Private equity firm Advent International said it has signed a definitive agreement to acquire a controlling stake in Hyderabad-based RA Chem Pharma Ltd from pharma firm Micro Labs

Advent International | Private equity firms

Press Trust of India  |  New Delhi 

stake, share, investment, equity, shareholder, promoter, banks, disinvestment, markets, returns, stocks,diversification
Representative image

Private equity firm on Thursday said it has signed a definitive agreement to acquire a controlling stake in Hyderabad-based RA Chem Pharma Ltd from pharma firm Micro Labs.

Though Advent did not provide any financial details or the percentage of the stake to be acquired, sources in know of the matter said the deal gives RA Chem Pharma an enterprise value of around Rs 1,000 crore.

They also said the PE firm is acquiring up to 60 per cent stake in the pharmaceutical company.

"We continue to be excited about India's pharmaceutical landscape, and investing in RA Chem Pharma will further strengthen our presence in the sector," MD and Head (India) Shweta Jalan said in a statement.

The company aims to build one of the leading API (active pharmaceutical ingredient) platforms in India and will leverage its financial and operational resources globally to scale RA Chem Pharma both organically and inorganically, she added.

has significant experience in the healthcare industry globally, the statement from the PE firm said.

"We believe that this transaction will further build upon RA Chem's strengths to continue its journey to deliver high-quality, niche and specialised products to its customers globally," Micro Labs Chairman and MD Dilip Surana said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, July 30 2020. 21:11 IST